News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
StocksToTrade Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Lumentum Holdings Inc. (LITE) saw its stock close up 5.18% on August 14, driven by strong quarterly results, increased forward guidance, and significant institutional buying due to AI infrastructure spending and optical demand. Despite some temporary pullbacks from valuation concerns and insider selling, the …
Lumentum stock keeps winning on AI optics demand. Now its 680% gain raises a different question: how much should investors own?
Sharemaestro market context Trend signal active 52 weeks +568.7% · Next-week setup negative 37.5%Shares of optical technology leaders Lumentum Holdings Inc. (NASDAQ:LITE) and Coherent Corp. (NYSE:COHR) experienced some action after the quarterly reports. During the August 12 episode of CNBC's Mad Money, Jim Cramer highlighted the short-term disconnect between market trading dynamics and business fundamentals in the …
Sharemaestro market context Trend signal active 52 weeks +568.7% · Next-week setup negative 37.5%Belite Bio (BLTE) is currently undervalued by 21% according to Simply Wall St. following the FDA's acceptance of its New Drug Application for tinlarebant with Priority Review. Despite a recent one-day dip, the stock has shown strong momentum over the last month and year, …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that …
Belite Bio CEO Lin Yu-Hsin sold 365 American depositary shares worth over $65,000 on August 12, 2026, as part of a Rule 10b5-1 trading plan. Despite the stock's remarkable 141% return over the past year, shares have recently declined to $166.28 from the transaction …
A Schedule 13G filing reveals that three affiliated broker-dealers—G1 Execution Services, LLC, SIG Brokerage, LP, and Susquehanna Securities, LLC—collectively hold a 6.9% beneficial ownership in AmpliTech Group, Inc. This stake amounts to 1,744,929 shares, based on 25,338,799 shares outstanding as of May 11, 2026. …
Quick Read Applied Optoelectronics surged 15% and Lumentum jumped 6%, with the intraday rally building on recent earnings strength and no confirmed same-day catalyst. Broadcom dropped 5% as component suppliers rallied, with Wolfe Research flagging its $30B in residual value guarantees as a longer-term …
Sharemaestro market context Trend signal active 52 weeks +568.7% · Next-week setup negative 37.5%This article provides stock information for Lite Strategy, Inc. (NASDAQ: LITS), detailing its share price, recent changes, active day range, and 52-week range. It also includes fundamental data such as previous close, market cap, volume, and revenue. The content emphasizes that the information is …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to …
Lumentum Holdings Inc. announced its participation in five investor events scheduled from August 17 to September 10, 2026. These events include technology summits and conferences hosted by Rosenblatt, Nasdaq, Deutsche Bank, Citi, and Wolfe Research, where Lumentum management will be available for meetings and …
The stock market cleared a tight range, with the S&P 500 and Russell 2000 hitting new highs. Lumentum, Cisco, Super Micro, Sandisk were key movers. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +568.7% · Next-week setup negative 37.5%Benchmark reiterated a Buy rating and a $217.00 price target for Belite Bio (NASDAQ:BLTE) after the FDA granted Priority Review to the company's New Drug Application for Tinlarebant, setting a PDUFA target date of February 12, 2027. The company plans a commercial launch in …
Belite Bio CEO Yu-Hsin Lin sold 365 shares of the company's stock for a total of $65,827.75, reducing his ownership by 0.21%. Despite the sale, analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $204.40, especially following the …
Mizuho has increased its price target for Belite Bio (NASDAQ:BLTE) to $220 from $215, while reaffirming an Outperform rating on the stock. This adjustment reflects a continued positive outlook from the analyst firm. The biopharmaceutical company is focused on developing novel therapeutics for retinal …
This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Belite Bio Inc (NASDAQ:BLTE) received FDA acceptance of its New Drug Application (NDA) for Tinlarabant …
AmpliTech Group, Inc. reported its Q2 2026 financial results, showing a decrease in revenue to $8.07M from $11.03M in the prior year, alongside a wider net loss of $3.09M and a diluted loss per share of $0.12. The company noted improved gross profit due …
Earnings Call Insights: AmpliTech Group, Inc. (AMPG) Q2 2026 MANAGEMENT VIEW * CEO Fawad Maqbool described Q2 as “an important period in AmpliTech's continued transformation and growth,” adding that results reflected “a deliberate increase in investment as we position AmpliTech to pursue and support …
Earnings Call Insights: Belite Bio (BLTE) Q2 2026 MANAGEMENT VIEW * Dr. Tom Lin (Chairman of the Board of Directors & CEO) framed the quarter around U.S. regulatory timing, saying, "the FDA has accepted our new drug application for Tinlarebant with priority review and …
AmpliTech Group reported Q2 2026 revenue of $8.07 million, significantly missing Wall Street's forecast of $13 million, leading to a sharp selloff in its stock. The company attributed the revenue miss to customer deployment timing shifts and subsequently withdrew its full-year guidance. Despite a …
Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …
AmpliTech Group (NASDAQ:AMPG) reported a quarterly loss of $0.12 per share, missing analyst estimates by $0.10, although revenue of $8.07 million slightly exceeded expectations. Following these results, the company's stock fell 6.6% to $5.99. Insider selling of shares has also been noted, while analysts …
AmpliTech Group announced strong financial results for Q2 2026, with revenue reaching $8.07 million, a 50.9% sequential increase, and gross profit soaring by 161.2% year-over-year to $2.25 million. The company is actively scaling commercialization across its 5G/telecommunications, SATCOM, defense, and semiconductor markets, supported by …
Search by ticker symbol or company name and select a result to open its chart.